Santersus AG

Santersus AG is a Swiss-based startup focused on revolutionizing the therapeutic treatment of patients in various areas through the selective extra corporeal removal of NETs and cell-free DNA from blood. The company's patented NucleoCapture apheresis device utilizes biocompatible, highly porous polymer beads conjugated with proprietary human recombinant histone H1.3 protein to achieve over 95% removal of NETs from contaminated blood in a single pass, without compromising the defensive function of neutrophils. Founded in 2017, Santersus AG operates in the Health Care and Manufacturing industries. The company has received phenomenal feedback from its diagnostic capability feasibility study, paving the way for further development and market achievement in 2021. With its innovative technology and promising results, Santersus AG presents a disruptive approach to therapeutic apheresis in critical care. The company's focus on addressing serious diseases through advanced blood purification methods positions it as a compelling player in the healthcare sector. While specific investment details are not available, Santersus AG's unique strategy and potential for market impact make it an intriguing prospect for venture capital firms seeking opportunities in the healthcare and biotechnology space.